284 related articles for article (PubMed ID: 29198080)
1. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
Shin H; Cho MC; Kim RB; Kim CH; Choi NC; Kim SK; Koh EH
J Thromb Thrombolysis; 2018 Feb; 45(2):250-256. PubMed ID: 29198080
[TBL] [Abstract][Full Text] [Related]
2. Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation.
Nissan R; Spectre G; Hershkovitz A; Green H; Shimony S; Cooper L; Nakav S; Shochat T; Grossman A; Fuchs S
Drugs Aging; 2019 Feb; 36(2):165-177. PubMed ID: 30460518
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
[TBL] [Abstract][Full Text] [Related]
4. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
[TBL] [Abstract][Full Text] [Related]
6. Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation.
Osanai H; Ajioka M; Masutomi T; Kuwayama T; Ishihama S; Sakamato Y; Otaka N; Sakaguchi T; Inoue Y; Kanbara T; Nakashima Y; Asano H; Sakai K
Circ J; 2015; 79(12):2584-90. PubMed ID: 26439323
[TBL] [Abstract][Full Text] [Related]
7. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
[TBL] [Abstract][Full Text] [Related]
9. Influence of age on the relationship between apixaban concentration and anti-factor Xa activity in older patients with non-valvular atrial fibrillation.
Kalaria SN; Zhu H; Liu Q; Florian J; Wang Y; Schwartz J
Int J Cardiol; 2021 May; 331():109-113. PubMed ID: 33529664
[TBL] [Abstract][Full Text] [Related]
10. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
Samoš M; Bolek T; Stančiaková L; Škorňová I; Bánovčin P; Kovář F; Staško J; Galajda P; Kubisz P; Mokáň M
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002
[TBL] [Abstract][Full Text] [Related]
11. Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.
Roşian AN; Roşian ŞH; Kiss B; Ştefan MG; Trifa AP; Ober CD; Anchidin O; Buzoianu AD
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32316515
[TBL] [Abstract][Full Text] [Related]
12. Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily.
Ono R; Fukushima K; Yamazaki T; Yamashita D; Takahashi H; Hori Y; Nishimura K
Naunyn Schmiedebergs Arch Pharmacol; 2022 Feb; 395(2):159-166. PubMed ID: 34851448
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
[TBL] [Abstract][Full Text] [Related]
14. Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors.
Ono R; Nishimura K; Takahashi H; Hori Y; Fukushima K; Kobayashi Y
Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):323-336. PubMed ID: 36326895
[TBL] [Abstract][Full Text] [Related]
15. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
16. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
17. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
[TBL] [Abstract][Full Text] [Related]
18. Validation of apixaban anti-factor Xa assay and impact of body weight.
Wasan SM; Feland N; Grant R; Aston CE
Thromb Res; 2019 Oct; 182():51-55. PubMed ID: 31450008
[TBL] [Abstract][Full Text] [Related]
19. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
Harenberg J; Du S; Wehling M; Zolfaghari S; Weiss C; Krämer R; Walenga J
Clin Chem Lab Med; 2016 Feb; 54(2):275-83. PubMed ID: 26167981
[TBL] [Abstract][Full Text] [Related]
20. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
